`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners.
`
`Case: IPR2021-00816
`Patent No. 9,220,631
`
`PATENT OWNERS REQUEST FOR ORAL ARGUMENT
`PURSUANT TO 37 C.F.R. § 42.70(a)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2021-00816
`U.S. Patent 9,220,631
`
`Novartis Pharma AG, Novartis Technology LLC, and Novartis
`
`Pharmaceuticals Corp. (together “Patent Owners” or “Novartis”) respectfully
`
`requests oral argument pursuant to 37 C.F.R. § 42.70(a); the Board’s Scheduling
`
`Order (Paper 14); and the Board’s email correspondence dated June 10, 2022.
`
`Novartis has conferred with Petitioner Regeneron Pharmaceuticals,
`
`Inc.
`
`(“Petitioner”), and the parties agreed to request that the hearing, scheduled for July
`
`21, 2022, at 11:30 AM ET, be conducted in person at USPTO Headquarters in
`
`Alexandria, Virginia.
`
`Novartis also respectfully requests that an option be made available for in-
`
`house counsel to attend the hearing virtually, either by video or telephone.
`
`Petitioner does not object to this request.
`
`Pursuant to 37 C.F.R. § 42.70(a) and without waiving any issue not
`
`specifically identified herein, Novartis hereby submits this Request for Oral
`
`Argument on issues related to the patentability of the challenged claims of U.S.
`
`Patent No. 9,220,631. Novartis intends to discuss the issues raised in the parties’
`
`filings under the ongoing review, including but not limited to, the following:
`
`1. Any issues properly raised by Petitioner, including the Petition and
`
`Petitioner’s Reply, and any exhibits relied on therein;
`
`2. Any issues raised by the Board’s Institution Decision dated October 26,
`
`1
`
`
`
`2021 (Paper 13); and
`
`IPR2021-00816
`U.S. Patent 9,220,631
`
`
`3. Any issues addressed in Novartis’s papers, including in Novartis’s
`
`Response and Novartis’s Sur-Reply, and any exhibits relied on therein.
`
`Novartis requests the ability to reserve a portion of its total time for presenting
`
`sur-rebuttal arguments after Petitioner’s rebuttal. See November 2019 Consolidated
`
`Trial Practice Guide at 83.
`
`If oral argument will be held in-person at a hearing room in the USPTO
`
`Office, Novartis requests the ability to use a computer, projector, and screen to
`
`display possible demonstrative exhibits. Novartis also requests that the attorneys at
`
`Novartis’s counsel table be allowed to use computers.
`
`Dated: June 14, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/Elizabeth Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Allen & Overy LLP
`1221 Avenue of the Americas
`New York, NY 10020
`Tel: 212-610-6375
`elizabeth.holland@allenovery.com
`
`Counsel for Patent Owners Novartis
`Pharma AG, Novartis Technology
`LLC, and Novartis Pharmaceuticals
`Corporation
`
`2
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. 42.70(a), the undersigned hereby certifies that on June
`
`14, 2022 a copy of the foregoing PATENT OWNER’S REQUEST FOR ORAL
`
`ARGUMENT was served via electronic mail, as agreed to by counsel, upon the
`
`following counsel for Petitioner:
`
`Elizabeth S. Weiswasser (Reg. No. 55,721)
`Anish R. Desai (Reg. No. 73,760)
`Natalie Kennedy (Reg. No. 68,511)
`Andrew Gesior (Reg. No. 76,588)
`WEIL GOTSHAL & MANGES LLP
`767 Fifth Avenue
`New York, NY 10153
`
`Brian E. Ferguson (Reg. No. 36,801)
`Christopher Pepe (Reg. No. 73,851)
`Priyata Y. Patel (Reg. No. 76,861)
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street, N.W., Suite 600
`Washington, DC 20036
`
`Petra Scamborova
`Petra.scamborova@regeneron.com
`James T. Evans
`James.evans@regeneron.com (Reg. No. 64,377)
`Regeneron Pharmaceuticals, Inc.
`777 Old Saw Mill River Road
`Tarrytown, NY 10591
`
`Email: Regeneron.IPR.Service@weil.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/Frank ReDavid/
`Frank ReDavid
`Litigation Specialist
`Allen & Overy LLP
`
`
`Dated: June 14, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
